LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

Search

TransMedics Group Inc

Lezárt

SzektorEgészségügy

79.12 8.16

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

74.51

Maximum

80.66

Fő mutatók

By Trading Economics

Bevétel

-98M

7.3M

Értékesítés

13M

174M

P/E

Szektor átlag

17.272

49.712

Egy részvényre jutó nyereség

0.3

Profit margin

4.206

Munkavállalók

898

EBITDA

-4.9M

28M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+57.78% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. júl. 29.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

-745M

2.6B

Előző nyitás

70.96

Előző zárás

79.12

Hangulat hírek alapján

By Acuity

50%

50%

155 / 342 Rangsor szerint Healthcare

TransMedics Group Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Rólunk TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat